Last reviewed · How we verify
NCT05095688
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
trial in Heart Failure With Preserved Ejection Fraction in 50 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Chongqing Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 21 September 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Conditions studied
- Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →
- Arterial Stiffness — all drugs for Arterial Stiffness →
- Lipid Disorder — all drugs for Lipid Disorder →
Sponsor
Chongqing Medical University
Who can join
Adults 18 to 99, any sex, with Heart Failure With Preserved Ejection Fraction or Arterial Stiffness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05095688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Preserved Ejection Fraction
Currently open trials in the same condition.
- NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati · NA · recruiting
- NCT06937827 — Transitions of Care Clinic (TOCC) · NA · recruiting
- NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
- NCT06702501 — The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF) · NA · recruiting
- NCT06616974 — A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction · Phase 2 · recruiting
Other Chongqing Medical University trials
Trials by the same sponsor.
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT07503509 — Physiological Study of High PEEP in Noninvasive Ventilation · NA · recruiting
- NCT06118671 — The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community · NA · unknown
- NCT06272032 — Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis · EARLY_PHASE1 · unknown
- NCT05974566 — Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05095688 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Medical University
- Last refreshed: 27 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05095688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing